Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million From U.S. Department Of Defense For Botulinum Neurotoxin Treatment
SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced the U.S. Department of Defense (DOD) has awarded Ology Bioservices, Inc. (Ology), a wholly owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
Click here to read the full press release from Business Wire.
